Health Care & Life Sciences » Biotechnology | PanGen Biotech Inc.

PanGen Biotech Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
3,212
3,400
3,731
1,461
2,373
Cost of Goods Sold (COGS) incl. D&A
2,806
3,478
3,228
3,806
3,976
Gross Income
406
77
503
2,345
1,603
SG&A Expense
977
1,933
2,517
4,900
2,266
EBIT
-
2,021
2,023
7,271
3,891
Unusual Expense
-
146
-
-
1,263
Non Operating Income/Expense
47
23
53
9
10
Interest Expense
1,101
958
664
189
-
Pretax Income
1,604
3,012
2,620
7,200
4,917
Income Tax
237
892
17
2,074
2,099
Consolidated Net Income
1,367
2,120
2,638
5,125
7,016
Net Income
1,367
2,120
2,638
5,125
7,016
Net Income After Extraordinaries
1,367
2,120
2,638
5,125
7,016
Net Income Available to Common
1,367
2,120
2,638
5,125
7,016
EPS (Basic)
179.00
277.00
345.00
614.00
744.00
Basic Shares Outstanding
8
8
8
8
9
EPS (Diluted)
178.87
277.30
345.04
614.10
744.07
Diluted Shares Outstanding
8
8
8
8
9
EBITDA
299
1,046
968
6,129
3,105
Other Operating Expense
8
10
9
26
23
Non-Operating Interest Income
28
89
13
251
246

About PanGen Biotech

View Profile
Address
4/F, YeongtongInnoplex II
Suwon GY 16675
Korea, Republic Of
Employees -
Website http://www.pangen.com
Updated 09/14/2018
PanGen Biotech, Inc. engages in the development of biopharmaceutical products. Its products include biosimilar erythropoietin, factor VIII and biosimilar G-CSF. The company was founded on January 29, 2010 and is headquartered in Suwon, South Korea.